ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.1243G>A (p.Val415Ile) (rs587782770)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000132298 SCV000187383 uncertain significance Hereditary cancer-predisposing syndrome 2018-10-29 criteria provided, single submitter clinical testing The p.V415I variant (also known as c.1243G>A), located in coding exon 9 of the BRCA1 gene, results from a G to A substitution at nucleotide position 1243. The valine at codon 415 is replaced by isoleucine, an amino acid with highly similar properties. In one study of 100 unselected triple negative breast cancer patients, this variant was seen in a patient with a negative family history of breast and ovarian cancer (Muendlein A et al. <span style="font-family:arial,sans-serif">J. Cancer Res. Clin<span style="font-family:arial,sans-serif">. Oncol<span style="font-family:arial,sans-serif">. 2015 Nov;141(11):2005-12). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae RCV001081676 SCV000218586 likely benign Hereditary breast and ovarian cancer syndrome 2020-10-19 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000588638 SCV000296369 uncertain significance not provided 2019-11-03 criteria provided, single submitter clinical testing
Counsyl RCV000238907 SCV000489338 uncertain significance Breast-ovarian cancer, familial 1 2016-09-21 criteria provided, single submitter clinical testing
GeneDx RCV000588638 SCV000565925 uncertain significance not provided 2017-12-07 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.1243G>A at the cDNA level, p.Val415Ile (V415I) at the protein level, and results in the change of a Valine to an Isoleucine (GTT>ATT). Using alternate nomenclature, this variant would be defined as BRCA1 1362G>A. This variant has been observed in at least one individual with triple negative breast cancer (Muendlein 2015). BRCA1 Val415Ile was observed at an allele frequency of 0.03% (9/25,778) in individuals of European (Non-Finnish) ancestry in large population cohorts (Lek 2016). Since Valine and Isoleucine share similar properties, this is considered a conservative amino acid substitution. BRCA1 Val415Ile is located in a region known to interact with multiple proteins (Paul 2014). In-silico analyses, including protein predictors and evolutionary conservation, support that this variant does not alter protein structure or function. Based on currently available evidence, it is unclear whether BRCA1 Val415Ile is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000588638 SCV000698839 uncertain significance not provided 2017-06-12 criteria provided, single submitter clinical testing Variant summary: The BRCA1 c.1243G>A (p.Val415Ile) variant involves the alteration of a non-conserved nucleotide. It is located in serine rich (SR) domain of the protein (InterPro). 3/4 in silico tools predict a benign outcome for this variant (SNPsandGO not captured due to low reliability index). This variant was found in 5/121228 control chromosomes from ExAC at a frequency of 0.0000412, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). This variant has been reported in a triple negative breast cancer case who had negative family history of the breast or ovarian cancer (Muendlein_2015). It has also been reported in a database (UMD) four times without co-occurrence with other deleterious variants in BRCA1/2 genes. Multiple clinical diagnostic laboratories/reputable databases have classified this variant as uncertain significance. Based on the currently available data, this variant has been classified as a Variant of Unknown Significance.
St. Jude Clinical Genomics Lab, St. Jude Children's Research Hospital RCV001081676 SCV000890996 uncertain significance Hereditary breast and ovarian cancer syndrome 2021-08-04 criteria provided, single submitter clinical testing
Color Health, Inc RCV000132298 SCV000910915 likely benign Hereditary cancer-predisposing syndrome 2017-08-21 criteria provided, single submitter clinical testing
Research and Development, ARUP Laboratories RCV001657814 SCV001878175 likely benign Breast-ovarian cancer, familial 2; Breast-ovarian cancer, familial 1; Hereditary breast and ovarian cancer syndrome 2020-01-20 criteria provided, single submitter curation

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.